Group 1 - Shares of Quanex Building Products (NX) have increased by 7.5% over the past four weeks, closing at $20.19, with a mean price target of $37 indicating a potential upside of 83.3% [1] - The mean estimate includes three short-term price targets with a standard deviation of $5.57, where the lowest estimate of $31 suggests a 53.5% increase, and the highest estimate of $42 indicates a potential surge of 108% [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as the Zacks Consensus Estimate for the current year has increased by 2.8% over the past month [11][12] Group 2 - NX holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside in the near term [13] - The clustering of price targets with a low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] - Despite skepticism around the reliability of price targets, the direction implied by them appears to be a useful guide for potential price movements [10]

Core Viewpoint - Perrigo (PRGO) shows potential for significant upside, with a mean price target of $36.67 indicating a 32.9% increase from the current price of $27.60 [1] Price Targets - The average price target consists of three estimates ranging from a low of $30 to a high of $42, with a standard deviation of $6.11, suggesting variability in analyst predictions [2] - The lowest estimate indicates an 8.7% increase, while the highest suggests a 52.2% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment - Analysts exhibit strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has increased by 0.1% over the past month, with no negative revisions [12] - PRGO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may be misleading, as analysts often set overly optimistic targets due to business incentives [8][10] - Empirical research indicates that price targets rarely predict actual stock price movements, suggesting a need for skepticism [7][10]

Core Viewpoint - Veris Residential (VRE) shares have shown a slight increase of 0.2% over the past four weeks, closing at $15.33, with a potential upside of 25.9% based on Wall Street analysts' mean price target of $19.30 [1][11]. Price Targets and Analyst Estimates - The mean estimate for VRE comprises five short-term price targets with a standard deviation of $4.02, indicating variability among analysts; the lowest estimate suggests a 4.4% increase to $16, while the highest predicts a surge of 69.6% to $26 [2][9]. - Analysts have recently shown increasing optimism regarding VRE's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has risen by 2.5% over the past month, with two estimates increasing and no negative revisions [12]. Analyst Behavior and Price Target Reliability - There is skepticism regarding the reliability of analysts' price targets, as empirical research indicates that these targets often mislead investors rather than provide accurate guidance [7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations for stocks they cover [8]. - A low standard deviation in price targets suggests a high degree of agreement among analysts about the stock's price direction, serving as a starting point for further research [9]. Investment Ranking - VRE currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside in the near term [13].

Core Viewpoint - Glaukos (GKOS) shows potential for significant upside, with a mean price target of $128.54 indicating a 34.4% increase from the current price of $95.64, supported by positive earnings estimate revisions [1][11]. Price Targets - The average of 13 short-term price targets ranges from a low of $72 to a high of $182, with a standard deviation of $33.39, indicating variability in analyst estimates [2]. - The lowest estimate suggests a decline of 24.7%, while the most optimistic estimate indicates a potential upside of 90.3% [2]. Analyst Consensus - Analysts have shown strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11]. - The Zacks Consensus Estimate for the current year has increased by 11.8%, with four estimates moving higher and no negative revisions [12]. Zacks Rank - GKOS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Caution on Price Targets - Solely relying on price targets for investment decisions may be misleading, as analysts often set overly optimistic targets influenced by business relationships [3][8][10].

Core Viewpoint - Byrna Technologies Inc. (BYRN) has seen a 16.8% increase in share price over the past four weeks, closing at $28.79, with a potential upside of 26.8% based on Wall Street analysts' mean price target of $36.50 [1] Group 1: Price Targets and Analyst Estimates - The mean price target consists of three short-term estimates with a standard deviation of $3.12, indicating a range of potential outcomes; the lowest estimate suggests a 14.6% increase to $33, while the highest predicts a 35.5% surge to $39 [2] - Analysts' consensus on earnings estimates has improved, with a positive trend in revisions indicating potential upside for BYRN, as historical data shows a strong correlation between earnings estimate revisions and stock price movements [4][11] - The Zacks Consensus Estimate for the current year has increased by 1.5% due to one upward revision and no negative revisions in the last 30 days, reflecting growing optimism among analysts [12] Group 2: Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can mislead investors; empirical research suggests that price targets rarely indicate actual stock price movements [7][8] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price direction, serving as a starting point for further research into fundamental drivers [9] - While price targets should not be the sole basis for investment decisions, they can provide useful directional guidance when considered alongside other factors [10][13]

Group 1 - FuelCell Energy (FCEL) closed at $6.72, with a 57% gain over the past four weeks, and a mean price target of $9.38 indicating a 39.6% upside potential [1] - The average price targets range from a low of $5 to a high of $13.75, with a standard deviation of $3.19, suggesting variability in analyst estimates [2] - Analysts show strong agreement on FCEL's ability to report better earnings, with positive trends in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for FCEL has increased by 0.3% over the past month, indicating a positive outlook with no negative revisions [12] - FCEL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for potential price movements [13]

Core Viewpoint - StoneX Group Inc. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on an upward trend in earnings estimates, which significantly influences stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates in determining near-term stock price movements, making it a valuable tool for investors [2][3]. - Institutional investors utilize earnings estimates to assess the fair value of stocks, leading to significant price movements based on their buying or selling activities [3]. Business Improvement Indicators - The increase in earnings estimates and the Zacks rating upgrade suggest an improvement in StoneX Group's underlying business, which could lead to higher stock prices as investors respond positively [4]. Earnings Estimate Revisions - For the fiscal year ending September 2025, StoneX Group is expected to earn $5.83 per share, with a 0.4% increase in the Zacks Consensus Estimate over the past three months [7]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [6]. - The upgrade of StoneX Group to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].

Core Viewpoint - Sangoma Technologies Corporation (SANG) shows potential for significant upside, with a mean price target of $8.42 indicating a 47.2% increase from the current price of $5.72 [1] Price Targets - The average price target consists of five estimates ranging from a low of $7.94 to a high of $9.50, with a standard deviation of $0.67, suggesting a consensus among analysts [2] - The lowest estimate indicates a potential increase of 38.8%, while the highest suggests a 66.1% upside [2] Analyst Sentiment - Analysts exhibit strong agreement on SANG's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 7.8%, with one estimate moving higher and no negative revisions [12] Zacks Rank - SANG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Intuitive Surgical, Inc. (ISRG) .Intuitive Surgical currently has an average brokerage recommen ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Axon Enterprise (AXON) .Axon currently has an average brokerage recommenda ...